UNITED THERAPEUTICS CORP (UTHR) Stock News
NASDAQ:UTHR - Nasdaq - US91307C1027 - Common Stock - Currency: USD
UTHR Latest News, Press Relases and Analysis
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%.
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%.
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
FDA Greenlights Studies of Pig Kidney Transplants in Humans
The US Food and Drug Administration approved clinical trials that will transplant organs from genetically modified pigs into patients with kidney failure.
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
United Therapeutics Announces Successful World’s First UKidney Transplant
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
Electric Aircraft Startup Beta Raises $318 Million in New Round
Electric aerospace startup Beta Technologies Inc. raised $318 million from investors to fund the production of aircraft that can takeoff and land vertically.
Mentions: FIS
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.